JPMorgan Chase & Co. trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,266 shares of the biopharmaceutical company’s stock after selling 7,720 shares during the period. JPMorgan Chase & Co. owned 0.06% of Alnylam Pharmaceuticals worth $4,409,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Alnylam Pharmaceuticals by 22.0% in the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 2,093 shares during the period. Hemenway Trust Co LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $235,000. BlackRock Inc. increased its position in Alnylam Pharmaceuticals by 34,755.2% in the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares during the period. Federated Investors Inc. PA increased its position in Alnylam Pharmaceuticals by 522.9% in the 2nd quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock worth $4,968,000 after buying an additional 52,293 shares during the period. Finally, Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $320,000. 94.25% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 122.65 on Friday. The company has a 50-day moving average price of $94.74 and a 200 day moving average price of $74.88. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $125.96. The firm’s market cap is $11.25 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.05) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current fiscal year.

Several research analysts have commented on ALNY shares. Cowen and Company reaffirmed a “buy” rating and issued a $100.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $62.00 to $163.00 in a research report on Monday, October 2nd. Jefferies Group LLC set a $102.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Barclays PLC lifted their price target on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 10th. Finally, Credit Suisse Group lifted their price target on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $100.80.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Position Decreased by JPMorgan Chase & Co.” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-position-decreased-by-jpmorgan-chase-co/1616872.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.